Researchers create triple-negative breast cancer organoids
Scientists have opened a path towards triple-negative breast cancer treatment, by creating organoids from tumour samples.
List view / Grid view
Oncology is a branch of medicine that deals with the prevention, diagnosis and treatment of cancer.
Scientists have opened a path towards triple-negative breast cancer treatment, by creating organoids from tumour samples.
New research from the Karolinska Institutet shows that RNA molecules have a much broader function in the development of cancer.
Researchers have been able to slow down the progression of glioblastoma in mice, the most common adult brain cancer.
Avacta Group announced that the chemotherapy candidate AVA3996 will be developed with a view to a first-in-human clinical trial beginning in 2023.
During investigations into the tropical disease Buruli ulcer, researchers have instead identified a promising new avenue for potential treatments for multiple myeloma.
A team of researchers in the US has devised a new means of removing excess chemotherapy drugs from a patient’s bloodstream, with potential for wider clinical and materials science applications.
In this article, Patrick Kendall, Scientific Advisor for Artelo Biosciences, outlines why future treatment of cancer anorexia-cachexia syndrome may lie with drugs in development offering a mechanistic approach.
Dr Alasdair Gunn and Natalie Bath from Adaptimmune explain how flow cytometry provides a useful tool for the development of immuno-oncology therapies. They also explore how they use this method for translational research of the company’s SPEAR T-cell products.
The new nanotechnology left six of 10 mice with lymphoma tumour-free and was effective in melanoma when combined with existing drugs.
The new study looked at the network of gene-gene interactions associated with cancer onset and progression to identify therapeutic targets.
A new study provides an in-depth review on the designs and applications of morphology-transformable nanoparticles to improve cancer therapies.
Scientists identified three prototypical RNA-expression states and revealed differences in their susceptibility to a variety of cancer drugs.
The new nanoparticle adjuvant improved antibody production following vaccination against HIV, diphtheria and influenza in mouse models.
Scientists used a new screen to identify FAM72A as a cause of mutagenesis that affects antibody development in COVID-19 and cancer.
Scientists develop organoid models of neuroendocrine prostate cancer to study EZH2 inhibitors and reveal a potential new target.